BioVersys says FDA grants Fast Track designation for BV100 antibiotic candidate

PUBT · 2d ago
BioVersys says FDA grants Fast Track designation for BV100 antibiotic candidate
  • BioVersys won FDA Fast Track status for BV100 to treat HABP or VABP caused by carbapenem-resistant Acinetobacter baumannii complex.
  • Designation supports its Phase 3 program. It also enables closer FDA interaction, faster review timelines, rolling submission eligibility.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bioversys AG published the original content used to generate this news brief via EQS News (Ref. ID: corporate_2392090_en) on September 02, 2026, and is solely responsible for the information contained therein.